1. Home
  2. VCV vs STTK Comparison

VCV vs STTK Comparison

Compare VCV & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Invesco California Value Municipal Income Trust

VCV

Invesco California Value Municipal Income Trust

N/A

Current Price

$9.19

Market Cap

487.7M

Sector

Finance

ML Signal

N/A

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$4.45

Market Cap

474.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VCV
STTK
Founded
N/A
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
487.7M
474.6M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
VCV
STTK
Price
$9.19
$4.45
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
★ $15.40
AVG Volume (30 Days)
216.9K
★ 925.0K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 53.02
EPS
★ N/A
N/A
Revenue
N/A
★ $1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$14.28
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$8.70
$1.93
52 Week High
$11.38
$8.33

Technical Indicators

Market Signals
Indicator
VCV
STTK
Relative Strength Index (RSI) 44.33 35.65
Support Level $8.78 $4.38
Resistance Level $10.80 $7.66
Average True Range (ATR) 0.15 0.38
MACD -0.03 -0.02
Stochastic Oscillator 11.67 8.14

Price Performance

Historical Comparison
VCV
STTK

About VCV Invesco California Value Municipal Income Trust

Invesco California Value Municipal Income Trust is a closed-end management investment company. Its investment objective is to provide common shareholders with a high level of current income, exempt from federal and California income taxes, consistent with the preservation of capital.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: